Current Topics in Microbiology and Immunology

Volume 347

Series Editors
Klaus Aktories
Albert-Ludwigs-Universität Freiburg, Medizinische Fakultät, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Abt. I, Albertstr. 25, 79104 Freiburg, Germany

Richard W. Compans
Emory University School of Medicine, Department of Microbiology and Immunology, 3001 Rollins Research Center, Atlanta, GA 30322, USA

Max D. Cooper
Department of Pathology and Laboratory Medicine, Georgia Research Alliance, Emory University, 1462 Clifton Road, Atlanta, GA 30322, USA

Yuri Y. Gleba
ICON Genetics AG, Biozentrum Halle, Weinbergweg 22, Halle 6120, Germany

Tasuku Honjo
Department of Medical Chemistry, Kyoto University, Faculty of Medicine, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan

Hilary Koprowski
Thomas Jefferson University, Department of Cancer Biology, Biotechnology Foundation Laboratories, 1020 Locust Street, Suite M85 JAH, Philadelphia, PA 19107-6799, USA

Bernard Malissen
Centre d’Immunologie de Marseille-Luminy, Parc Scientifique de Luminy, Case 906, Marseille Cedex 9 13288, France

Fritz Melchers
Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany

Michael B.A. Oldstone
Viral Immunobiology Laboratory, Dept. of Immunology & Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines, La Jolla, CA 92037, USA

Sjur Olsnes
Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello 0310 Oslo, Norway

Peter K. Vogt
The Scripps Research Institute, Dept. of Molecular & Experimental Medicine, 10550 North Torrey Pines Road. BCC-239, La Jolla, CA 92037, USA
Current Topics in Microbiology and Immunology

Previously published volumes
Further volumes can be found at springer.com

Vol. 321: Beutler, Bruce (Ed.):
Immunology, Phenotype First: How Mutations Have Established New Principles and Pathways in Immunology. 2008.
ISBN 978-3-540-75202-8

Vol. 322: Romeo, Tony (Ed.):
Bacterial Biofilms. 2008.
ISBN 978-3-540-75417-6

Vol. 323: Tracy, Steven; Oberste, M. Steven; Drescher, Kristen M. (Eds.):
Group B Coxsackieviruses. 2008.
ISBN 978-3-540-75545-6

Vol. 324: Nomura, Tatsuji; Watanabe, Takeshi; Habu, Sonoko (Eds.):
ISBN 978-3-540-75646-0

Vol. 325: Shenk, Thomas E.; Stinski, Mark F. (Eds.):
ISBN 978-3-540-77348-1

Vol. 326: Reddy, Anireddy S.N; Golovkin, Maxim (Eds.):
Nuclear pre-mRNA processing in plants. 2008.
ISBN 978-3-540-76775-6

Vol. 327: Manchester, Marianne; Steinmetz, Nicole F. (Eds.):
Viruses and Nanotechnology. 2008.

Vol. 328: van Etten, (Ed.):
Lesser Known Large dsDNA Viruses. 2008.
ISBN 978-3-540-68617-0

Vol. 329: Griffin, Diane E.; Oldstone, Michael B.A. (Eds.):
Measles. 2009.
ISBN 978-3-540-70917-0

Vol. 330: Griffin, Diane E.; Oldstone, Michael B.A. (Eds.):
Measles. 2009.
ISBN 978-3-540-70616-8

Vol. 331: Villiers, E. M. de (Ed.):
TT Viruses. 2009.
ISBN 978-3-540-70917-8

Vol. 332: Karasev A. (Ed.):
Plant produced Microbial Vaccines. 2009.

Vol. 333: Compans, Richard W.; Orenstein, Walter A. (Eds.):
Vaccines for Pandemic Influenza. 2009.
ISBN 978-3-540-92164-6

Vol. 334: McGavern, Dorian; Dustin, Micheal (Eds.):
ISBN 978-3-540-93862-0

Vol. 335: Levine, Beth; Yoshimori, Tamotsu; Deretic, Vojto (Eds.):
Autophagy in Infection and Immunity. 2009.
ISBN 978-3-642-00301-1

Vol. 336: Kielian, Tammy (Ed.):
ISBN 978-3-642-00548-0

Vol. 337: Sasakawa, Chihiro (Ed.):
Molecular Mechanisms of Bacterial Infection via the Gut. 2009.
ISBN 978-3-642-01845-9

Vol. 338: Rothman, Alan L. (Ed.):
Dengue Virus. 2009.
ISBN 978-3-642-02214-2

Vol. 339: Spearman, Paul; Freed, Eric O. (Eds.):
HIV Interactions with Host Cell Proteins. 2009.
ISBN 978-3-642-02174-9

Vol. 340: Saito, Takashi; Batista, Facundo D. (Eds.):
Immunological Synapse. 2010.
ISBN 978-3-642-03857-0

Vol. 341: Bruserud, Oystein (Ed.):
The Chemokine System in Clinical and Experimental Hematology. 2010.
ISBN 978-3-642-12638-3

Vol. 342: Arvin, Ann M. (Ed.):
Varicella-zoster Virus. 2010.
ISBN 978-3-642-12727-4

Vol. 343: Johnson, John E. (Ed.):
Cell Entry by Non-Enveloped Viruses. 2010.
ISBN 978-3-642-13331-2

Vol. 345: Simon, M. Celeste (Ed.):
Diverse Effects of Hypoxia on Tumor Progression. 2010.
ISBN 978-3-642-13328-2

Vol. 346: Christian Rommel; Bart Vanhaesebroeck; Peter K. Vogt (Ed.):
Phosphoinositide 3-kinase in Health and Disease. 2010.
ISBN 978-3-642-13662-7
Contents

PI3K: From the Bench to the Clinic and Back ............................................. 1
Bart Vanhaesebroeck, Peter K. Vogt, and Christian Rommel

Oncogenic Mutations of PIK3CA in Human Cancers ............................. 21
Yardena Samuels and Todd Waldman

Structural Effects of Oncogenic PI3Kα Mutations ................................. 43
Sandra B. Gabelli, Chuan-Hsiang Huang, Diana Mandelker,
Oleg Schmidt-Kittler, Bert Vogelstein, and L. Mario Amzel

Comparing the Roles of the p110α and p110β Isoforms
of PI3K in Signaling and Cancer ......................................................... 55
Nina Ilić and Thomas M. Roberts

Phosphatidylinositol 3-Kinase: The Oncoprotein .................................. 79
Peter K. Vogt, Jonathan R. Hart, Marco Gymnopoulos, Hao Jiang,
Sohye Kang, Andreas G. Bader, Li Zhao, and Adam Denley

AKT Signaling in Physiology and Disease ............................................. 105
Krishna M. Vasudevan and Levi A. Garraway

Faithful Modeling of PTEN Loss Driven Diseases in the Mouse ............ 135
Caterina Nardella, Arkaitz Carracedo, Leonardo Salmena,
and Pier Paolo Pandolfi

PI3K as a Target for Therapy in Haematological Malignancies ............ 169
Asim Khwaja

Clinical Development of Phosphatidylinositol-3 Kinase
Pathway Inhibitors ............................................................................. 189
Carlos L. Arteaga
<table>
<thead>
<tr>
<th>From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development</th>
<th>209</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saveur-Michel Maira, Peter Finan, and Carlos Garcia-Echeverria</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)</th>
<th>241</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morris E. Feldman and Kevan M. Shokat</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Small Molecule Inhibitors of the PI3-Kinase Family</th>
<th>263</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zachary A. Knight</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance</th>
<th>279</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qi-Wen Fan and William A. Weiss</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Index</th>
<th>297</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Contributors

L. Mario Amzel  Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA, mamzel@jhmi.edu

Carlos L. Arteaga  Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA and Department of Cancer Biology, Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA and Division of Oncology, VUMC, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232-6307, USA, carlos.arteaga@vanderbilt.edu

Andreas G. Bader  Mirna Therapeutics Inc. 2150 Woodward, Suite 100, Austin, TX 78744, USA

Arkaitz Carracedo  Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Adam Denley  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Qi-Wen Fan  Departments of Neurology, University of California, 1450 3rd St, MC0520, San Francisco, CA 94158-9001, USA

Morris E. Feldman  Howard Hughes Medical Institute, UC San Francisco, 600 16th St., Genentech Hall, San Francisco, CA 94158, USA and Department of Cellular and Molecular Pharmacology, UC San Francisco, 600 16th St., Genentech Hall, San Francisco, CA 94158, USA
Contributors

Peter Finan  Novartis Institutes for Biomedical Research, Cambridge, USA

Sandra B. Gabelli  Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA, gabelli@jhmi.edu

Carlos Garcia-Echeverría  Oncology Drug Discovery, Novartis Institutes for Biomedical Research, 13, quai Jules Guesde, 94403 Vitry-sur-Seine Cedex, France, carlos.garcia-echeverria@sanofi-aventis.com

Levi A. Garraway  Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA and The Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA, levi_garraway@dfci.harvard.edu

Marco Gymnopoulos  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Jonathan R. Hart  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Chuan-Hsiang Huang  Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA and Department of Cell Biology and Anatomy, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Nina Ilić  Dana-Farber Cancer Institute, Department of Cancer Biology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA

Hao Jiang  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Sohye Kang  Amgen, One Amgen Center Drive, Thousand Oaks, CA 91320, USA

Asim Khwaja  UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK, a.khwaja@ucl.ac.uk
Zachary A. Knight  The Rockefeller University, 1230 York Ave, New York, NY 10065, USA, zknight@rockefeller.edu

Saveur-Michel Maira  Oncology Drug Discovery, Novartis Institutes for Biomedical Research, 13, quai Jules Guesde, 94403 Vitry-sur-Seine Cedex, France

Diana Mandelker  Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA

Caterina Nardella  Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Pier Paolo Pandolfi  Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA, ppandolf@bidmc.harvard.edu

Thomas M. Roberts  Dana-Farber Cancer Institute, Department of Cancer Biology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA, Thomas_Roberts@dfci.harvard.edu

Christian Rommel  Intellikine Inc., 10931 North Torrey Pines Road, La Jolla, CA 92037, USA

Leonardo Salmena  Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Yardena Samuels  Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA, samuelsy@mail.nih.gov

Oleg Schmidt-Kittler  Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA

Kevan M. Shokat  Howard Hughes Medical Institute, UC San Francisco, 600 16th St., Genentech Hall, San Francisco, CA 94158, USA and Department of
Bart Vanhaesebroeck  Centre for Cell Signalling, Institute of Cancer, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK, bart.vanh@qmul.ac.uk

Krishna M. Vasudevan  Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

Bert Vogelstein  Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA

Peter K. Vogt  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Todd Waldman  Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA

William A. Weiss  Departments of Neurology, University of California, 1450 3rd St, MC0520, San Francisco, CA 94158-9001, USA and Pediatrics, University of California, 1450 3rd St, MC0520, San Francisco, CA 94158-9001, USA and Neurological Surgery and Brain Tumor Research Center, University of California, 1450 3rd St, MC0520, San Francisco, CA 94158-9001, USA and Helen Diller Family Comprehensive Cancer Center, University of California, 1450 3rd St, MC0520, San Francisco, CA 94158-9001, USA, weiss@cgl.ucsf.edu

Li Zhao  Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA